Endothelial Glycocalyx Restoration Therapies in Cardiovascular Disease

Abstract

The endothelial glycocalyx, a dynamic carbohydrate-rich layer lining the vascular endothelium, plays a pivotal role in vascular homeostasis, mechanotransduction, and barrier function. Its degradation has been implicated in the pathogenesis and progression of various cardiovascular diseases (CVD), including atherosclerosis, heart failure, and microvascular dysfunction. This review comprehensively examines the current state of endothelial glycocalyx restoration therapies, discusses their mechanistic rationale, evaluates recent advances in translational research, and provides clinically relevant insights for cardiovascular medicine. Special attention is given to epidemiological data, risk factors, pathophysiological mechanisms, clinical features, diagnostic strategies, and guideline-based management in the context of glycocalyx-targeted interventions.

Introduction

The cardiovascular system's integrity heavily relies on the health of the vascular endothelium and, by extension, the endothelial glycocalyx. The glycocalyx serves as a crucial interface between circulating blood elements and the endothelial cell surface, mediating vascular permeability, shear stress sensing, and anti-inflammatory signaling. Damage to the glycocalyx has emerged as a central event in the development of CVD. With growing recognition of its clinical relevance, research efforts have shifted towards exploring therapeutic strategies aimed at restoring or preserving the glycocalyx as a novel approach to cardiovascular protection. This article synthesizes current scientific knowledge and recent clinical advances in glycocalyx restoration within the context of cardiovascular disorders.

Epidemiology / Disease Burden

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, accounting for over 17 million deaths annually. Epidemiological studies have revealed that endothelial dysfunction, closely linked to glycocalyx degradation, is prevalent in patients with coronary artery disease, hypertension, diabetes mellitus, and heart failure. The burden of glycocalyx-related endothelial injury is heightened in populations with metabolic syndrome and chronic inflammatory conditions. Quantitative assessments, such as perfused boundary region (PBR) measurements, have correlated glycocalyx thinning with adverse cardiovascular outcomes, highlighting the significance of this structure in disease stratification and prognosis.

Pathophysiology

The endothelial glycocalyx is composed of proteoglycans, glycosaminoglycans (GAGs), glycoproteins, and associated plasma proteins. It acts as a selective barrier, modulating vascular permeability, leukocyte adhesion, and thrombogenicity. Glycocalyx degradation occurs via enzymatic cleavage by heparanase, hyaluronidase, and matrix metalloproteinases, as well as oxidative stress and inflammatory cytokines. Loss of glycocalyx integrity exposes the endothelium to increased shear stress, promotes leukocyte-endothelial interactions, platelet aggregation, and triggers microvascular leakage. This cascade underpins the pathogenesis of atherosclerosis, ischemia-reperfusion injury, and heart failure, making glycocalyx preservation a promising therapeutic target.

Risk Factors

Major risk factors for glycocalyx damage include hyperglycemia, hypertension, dyslipidemia, smoking, systemic inflammation, advanced age, and exposure to ischemia or reperfusion. Diabetes mellitus is notable for persistent hyperglycemia-induced oxidative stress, which accelerates GAG shedding. Additionally, sepsis and critical illness are associated with profound glycocalyx degradation, contributing to organ dysfunction and coagulopathy. Iatrogenic factors, such as fluid overload and certain pharmacologic agents, may also disrupt glycocalyx structure and function.

Clinical Features

While direct visualization of the glycocalyx is challenging in clinical settings, its degradation is inferred from manifestations of endothelial dysfunction: increased vascular permeability, tissue edema, impaired vasodilation, microcirculatory disturbances, and heightened thrombotic risk. In acute coronary syndromes and heart failure, glycocalyx disruption correlates with elevated biomarkers such as syndecan-1 and hyaluronan, which serve as surrogate indicators of endothelial injury. The clinical consequences range from subclinical microvascular dysfunction to overt organ failure in critically ill patients.

Diagnosis

Diagnostic approaches for assessing glycocalyx status include indirect biomarkers (syndecan-1, hyaluronan, heparan sulfate), sublingual microvascular imaging using sidestream dark-field (SDF) or incident dark-field (IDF) microscopy, and measurement of the PBR. These modalities facilitate the evaluation of glycocalyx dimensions and function in vivo, offering prognostic value in acute and chronic cardiovascular conditions. Ongoing research aims to refine these techniques for routine clinical application and risk stratification.

Treatment & Management

Conventional cardiovascular risk factor modification remains fundamental in preventing further glycocalyx injury. Tight glycemic control, antihypertensive therapy, lipid-lowering agents, and smoking cessation indirectly support glycocalyx preservation. Volume management and judicious use of intravenous fluids are critical in hospitalized patients to avoid iatrogenic damage. Pharmacologic agents such as statins, angiotensin-converting enzyme inhibitors, and antioxidants have demonstrated glycocalyx-protective effects in preclinical and early clinical studies, primarily through anti-inflammatory and anti-oxidative mechanisms.

Recent Advances / Emerging Therapies

Novel strategies for direct glycocalyx restoration are under active investigation. Sulodexide, an oral GAG preparation, has shown promise in restoring glycocalyx thickness and improving endothelial function in diabetic and hypertensive cohorts. Recombinant human antithrombin, hydrocortisone, and albumin infusions have demonstrated potential benefits in acute settings by stabilizing glycocalyx components. Emerging therapies targeting heparanase inhibition and exogenous GAG supplementation are progressing through preclinical and early-phase clinical trials. Additionally, sphingosine-1-phosphate analogs and agents modulating endothelial nitric oxide synthase (eNOS) activity are being explored as modulators of glycocalyx resilience and recovery.

Guideline Recommendations

Although formal guideline endorsement of glycocalyx-targeted therapies in cardiovascular disease management is currently lacking, expert consensus supports aggressive risk factor control and the avoidance of known iatrogenic insults. International societies acknowledge the importance of endothelial health in CVD prevention, but specific recommendations regarding glycocalyx restoration await further validation from large-scale randomized clinical trials. Future guideline updates may incorporate emerging evidence as novel interventions demonstrate clinical efficacy and safety.

Conclusion

The endothelial glycocalyx represents a promising frontier in the management of cardiovascular disease. Its structural and functional integrity is essential for vascular health, and its degradation constitutes a key mechanism in CVD pathogenesis. Recent advances in diagnostic modalities and therapeutic strategies have expanded our understanding and ability to target glycocalyx injury. While robust clinical data are still forthcoming, integrating glycocalyx preservation into comprehensive cardiovascular care holds potential to reduce disease burden and improve patient outcomes. Ongoing research and future guideline updates are anticipated to further define the role of glycocalyx restoration in routine clinical practice.